Effects of HMG-CoA Reductase Inhibitors on Coagulation and Fibrinolysis Processes

被引：0
|
作者：
Robert Krysiak
Boguslaw Okopień
Zbigniew S. Herman
机构：
[1] Medical University of Silesia,Department of Clinical Pharmacology
来源：
Drugs | 2003年 / 63卷
关键词：
Simvastatin; Atorvastatin; Pravastatin; Human Umbilical Vein Endothelial Cell; Tissue Factor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Recent large clinical trials have demonstrated that HMG-CoA reductase inhibitors, or statins, markedly reduce morbidity and mortality when used in the primary and secondary prevention of cardiovascular disease. It has been established that the benefits of statin therapy in cardiovascular disease can be explained not only by the lipid-lowering potential of statins but also by nonlipid-related mechanisms (so-called ‘pleiotropic effects’) that contribute to the positive effect of statins on the incidence of cardiovascular events.
引用
收藏
页码：1821 / 1854
页数：33
相关论文
共 50 条
  • [21] Role of HMG-CoA Reductase Inhibitors in Neurological DisordersProgress to Date
    Allison B. Reiss
    Elzbieta Wirkowski
    Drugs, 2007, 67 : 2111 - 2120
  • [22] How do HMG-CoA reductase inhibitors prevent stroke?
    Bedi A.
    Flaker G.C.
    American Journal of Cardiovascular Drugs, 2002, 2 (1) : 7 - 14
  • [23] Evaluation of myopathy risk for HMG-CoA reductase inhibitors by urethane infusion method
    Matsuyama, K
    Nakagawa, K
    Nakai, A
    Konishi, Y
    Nishikata, M
    Tanaka, H
    Uchida, T
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2002, 25 (03) : 346 - 350
  • [24] HMG-CoA reductase inhibitors: Useful in stroke prevention?
    不详
    Drugs & Therapy Perspectives, 2001, 17 (2) : 10 - 12
  • [25] Safety of HMG-CoA Reductase Inhibitors: Focus on Atorvastatin
    Franco Bernini
    Andrea Poli
    Rodolfo Paoletti
    Cardiovascular Drugs and Therapy, 2001, 15 : 211 - 218
  • [26] HMG-CoA Reductase Inhibitors for Traumatic Brain Injury
    Katlowitz, Kalman
    Gopinath, Shankar
    Cruz Navarro, Jovany
    Robertson, Claudia
    NEUROTHERAPEUTICS, 2023, 20 (06) : 1538 - 1545
  • [27] Atorvastatin: A step ahead for HMG-CoA reductase inhibitors
    Black, DM
    PERFUSION, 1996, 9 (04): : 140 - 142
  • [28] Safety of HMG-CoA reductase inhibitors: Focus on atorvastatin
    Bernini, F
    Poli, A
    Paoletti, R
    CARDIOVASCULAR DRUGS AND THERAPY, 2001, 15 (03) : 211 - 218
  • [29] Drug–Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors
    Benoit Chauvin
    Sylvain Drouot
    Aurélie Barrail-Tran
    Anne-Marie Taburet
    Clinical Pharmacokinetics, 2013, 52 : 815 - 831
  • [30] Effects of HMG-CoA Reductase Inhibitors on the Pharmacokinetics of Losartan and Its Main Metabolite EXP-3174 in Rats: Possible Role of CYP3A4 and P-gp Inhibition by HMG-CoA Reductase Inhibitors
    Yang, Si-Hyung
    Choi, Jun-Shik
    Choi, Dong-Hyun
    PHARMACOLOGY, 2011, 88 (1-2) : 1 - 9
12345